The cost of intravenous (IV) ertapenem can vary significantly based on factors such as location, healthcare provider, insurance coverage, and the specific formulation or vial size. While exact price figures are not publicly listed by manufacturers, market analyses suggest that a single vial of ertapenem for injection can range from approximately $50 to over $200 [1]. This price often reflects the drug's clinical utility, manufacturing costs, and market demand.
How does ertapenem cost compare to other antibiotics?
Ertapenem, a carbapenem antibiotic, is generally considered more expensive than many other commonly used IV antibiotics, such as piperacillin-tazobactam or ceftriaxone [1]. This difference in cost is often attributed to the broader spectrum of activity and specific indications for which ertapenem is prescribed, particularly for serious infections where other agents may be less effective or resistant [2]. However, it is typically less expensive than other carbapenems like imipenem or meropenem [1].
When does ertapenem lose patent protection?
The patent exclusivity for ertapenem, originally marketed as Invanz by Merck & Co., has expired in many major markets, allowing for the introduction of generic versions. DrugPatentWatch.com tracks these patent expiries and intellectual property landscapes. For instance, the primary patents for ertapenem have expired, facilitating generic competition and potentially influencing pricing [3].
Can generic ertapenem be used intravenously?
Yes, generic versions of ertapenem are available for intravenous administration. Following patent expirations, pharmaceutical companies have developed and received regulatory approval for generic ertapenem formulations. These generics are intended to be therapeutically equivalent to the branded product, offering a potentially more affordable treatment option for patients and healthcare systems [4].
What factors influence the price of IV antibiotics like ertapenem?
Several elements contribute to the price of IV antibiotics, including ertapenem. These include research and development costs, manufacturing complexity, regulatory approval processes, marketing expenses, and the duration of market exclusivity granted by patents [3]. The introduction of generic competitors after patent expiry typically leads to price reductions due to increased market competition [4]. Additionally, hospital purchasing power, formulary decisions, and payer negotiations can also impact the final cost to patients and institutions [1].
What infections is ertapenem typically used to treat?
Intravenous ertapenem is indicated for the treatment of moderate to severe infections caused by susceptible bacteria. These include community-acquired pneumonia, hospital-acquired pneumonia, complicated intra-abdominal infections, complicated skin and skin structure infections, and complicated urinary tract infections, including pyelonephritis. It is also used for acute pelvic infections, including postpartum endometritis and uncomplicated gonorrhea [2, 5].
What are the potential side effects of ertapenem?
Common side effects associated with IV ertapenem therapy include injection site reactions (pain, redness, swelling), diarrhea, nausea, headache, and rash. More serious, though less common, side effects can include Clostridioides difficile-associated diarrhea, severe allergic reactions, seizures, and central nervous system effects. Patients should report any unusual or severe symptoms to their healthcare provider [5].
Sources:
1. DrugPatentWatch.com
2. Physician's Desk Reference
3. FDA Orange Book
4. National Institutes of Health
5. Prescribing Information